Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant tPA by Endovascular Administration for the Treatment of Submassive Pulmonary Embolism Using Pharmaco-mechanical Catheter Directed Thrombolysis for the redUction of Thrombus burdEn

NCT04248868 is registered in ClinicalTrials.gov with Thrombolex, Inc. as lead sponsor.

NCT NCT04248868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04248868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant tPA by Endovascular Administration for the Treatment of Submassive Pulmonary Embolism Using Pharmaco-mechanical Catheter Directed Thrombolysis for the redUction of Thrombus burdEn
Lead sponsor
Thrombolex, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 23, 2020
Completion date
June 23, 2022
Enrollment
109 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary embolism